The so-called molecular targeted therapy is to design the corresponding therapeutic drugs at the cellular molecular level, targeting the identified oncogenic sites (the site can be a protein molecule or a gene fragment inside the tumor cell). Therefore, molecular targeted therapy is also called “biological missile”. The introduction of molecular targeted therapy has not only changed the traditional chemotherapy treatment mode, but also improved the treatment rate of certain tumors. Targeted therapy has been gradually adopted for many malignant tumors, such as breast cancer, lymphoma, gastrointestinal cancer, lung cancer, mesenchymal tumor, and kidney cancer. Commonly used targeted therapies such as Troche, Erythroxel, Herceptin, Gleevec, Eptifibatol, etc. have been used in clinical practice. Since molecular targeted therapy has such amazing efficacy, can it be used by all breast cancer patients? Of course not, there are strict conditions for the use of molecular targeted therapy, it targets specific targets, just like a missile needs radar and satellites to help find and lock the target before launching, it also needs some auxiliary means. Targeted therapy also depends on patient-specific conditions. There are also disadvantages to targeted therapy drugs, which are more expensive and not covered by health insurance.